马萨诸塞州剑桥 - 拥有75.6%高毛利率的208亿美元生物技术公司Biogen Inc. (NASDAQ: BIIB )已进入关键阶段，美国和欧洲监管机构正在审查其用于治疗脊髓性肌萎缩症 (SMA)的nusinersen药物的高剂量方案。美国食品和药物管理局 (FDA)已接受该公司的补充新药申请 (sNDA)，欧洲药品管理局 (EMA)也已验证同一申请。

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, ...

SMA Solar Technology AG says it will open a new ... advantageous production location and the right approach,” the company said, noting that up to 200 new jobs will be created in the first ...

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...

The conditions for the railway technology spin out were drawn up over recent months at SMA and a corresponding spin out plan was agreed at the general meeting on April the 30th, 2008. The spin out of ...

The conditions for the railway technology spin out were drawn up over recent months at SMA and a corresponding spin out plan was agreed at the general meeting on April the 30th, 2008. The spin out of ...

The SAP, the Environmental Protection Agency, the U.S. Fish and Wildlife Service, the United Nations Environment Programme, and the European Union Network for the Center for International ...

The company plans to optimize its cost structure, adjust its organizational and operational setup, and strategically reposition itself in the market, according to SMA. “In order for SMA to ...

SMA Solar Technology (0NIF – Research Report) received a Buy rating and a €20.00 price target from Jefferies analyst Martin Comtesse today. The ...

DLTR's store and product expansion is promising, yet rising expenses and soft discretionary demand weigh on performance.

OXY is exposed to commodity price fluctuation, but investors can remain invested, given its strong Permian Basin and ...